ÂÜÀòÂÒÂ×

Jim Bagshaw is an experienced medical sales professional specializing in rare diseases. Currently serving as a Rare Disease Specialist at Zevra Therapeutics since January 2024, Jim focuses on the sales and reimbursement of the ultra-orphan drug Olpruva for Urea Cycle Disorders across the Midwest. Prior experience includes being an Executive Clinical Account Manager at Travere Therapeutics, where Jim achieved the top national ranking in new patient starts for Thiola, and a Rare Disease Regional Account Manager at Alexion Pharmaceuticals, responsible for sales of critical enzyme replacement therapies Strensiq and Kanuma. Jim's career spans over two decades with notable roles at Genzyme and Questcor Pharmaceuticals, consistently driving sales, access, and promotion for a variety of orphan and ultra-orphan treatments. Educational qualifications include a Bachelor of Science Degree in Marketing and Business Administration from the University of Southern Maine and additional studies at Temple University.